We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance.
[caption id="attachment_540497" align="aligncenter" width="750"]Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning oncology as its next growth engine...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.